A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis

Journal of the American Academy of Dermatology

Volumn 50, Issue 6, 2004, Pages 859-866

  Carlin, Christopher S ^a,f   Feldman, Steven R ^b   Krueger, James G ^c   Menter, Alan ^d   Krueger, Gerald G ^a,e  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^f MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEFACEPT; ANTIPSORIASIS AGENT; EFALIZUMAB; ETANERCEPT; METHOTREXATE;

ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DRUG EFFICACY; ERYTHEMA; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PSORIASIS; PSORIASIS AREA AND SEVERITY INDEX 50; QUALITY OF LIFE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 2542445474     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jaad.2003.09.014     Document Type: Article

References (52)

1. Jenisch S, Westphal E, Nair RP, Stuart P, Voorhees JJ, Christophers E, et al. Linkage disequilibrium analysis of familial psoriasis: identification of multiple disease-associated MHC haplotypes. Tissue Antigens 1999;53:135-46.
2. Ashcroft DM, Li Wan Po A, Williams HC, Griffiths CE. Quality of life measures in psoriasis: a critical appraisal of their quality. J Clin Pharm Ther 1998;23:391-8.
3. McKenna KE, Stern RS. The impact of psoriasis on the quality of life of patients from the 16-center PUVA follow-up cohort. J Am Acad Dermatol 1997;36:388-94.
4. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999;41:401-7.
5. Weiss SC, Kimball AB, Liewehr DJ, Blauvelt A, Turner ML, Emanuel EJ. Quantifying the harmful effect of psoriasis on health-related quality of life. J Am Acad Dermatol 2002;47:512-8.
6. Linden KG, Weinstein GD. Psoriasis: current perspectives with an emphasis on treatment. Am J Med 1999;107:595-605.
7. Krueger G, Koo J, Lebwohl M, Menter A, Stern RS, Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch Dermatol 2001;137:280-4.
8. Fredriksson T, Pettersson U. Severe psoriasis-oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
9. Kirby B, Fortune DG, Bhushan M, Chalmers RJ, Griffiths CE. The Salford Psoriasis Index: an holistic measure of psoriasis severity. Br J Dermatol 2000;142:728-32.
10. Feldman SR, Fleischer AB Jr, Reboussin DM, Rapp SR, Exum ML, Clark AR, et al. The self-administered psoriasis area and severity index is valid and reliable. J Invest Dermatol 1996;106:183-6.
11. Fleischer AB Jr, Feldman SR, Dekle CL. The SAPASI is valid and responsive to psoriasis disease severity changes in a multi-center clinical trial. J Dermatol 1999;26:210-5.
12. Krueger GG. New method being developed for assessing psoriasis. National Psoriasis Foundation Forum 1999;5:4-5.
13. Ashcroft DM, Wan Po AL, Williams HC, Griffiths CE. Clinical measures of disease severity and outcome in psoriasis: a critical appraisal of their quality. Br J Dermatol 1999;141:185-91.
14. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000;356:385-90.
15. Ellis CN, Krueger GG. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55.
16. Bhushan M, Bleiker TO, Ballsdon AE, Allen MH, Sopwith M, Robinson MK, et al. Anti-E-selectin is ineffective in the treatment of psoriasis: a randomized trial. Br J Dermatol 2002;146:824-31.
17. Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory Committee 49th Meeting [minutes from meeting]; March 20, 1998.
18. Food and Drug Administration. Dermatologic and Ophthalmic Drugs Advisory Committee Meeting [minutes from meeting]; May 23, 2002.
19. Krueger GG, Papp KA, Stough DB, Loven KH, Gulliver WP, Ellis CN. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002;47:821-33.
20. Krueger JG, Wolfe JT, Nabeya RT, Vallat VP, Gilleaudeau P, Heftler NS, et al. Successful ultraviolet B treatment of psoriasis is accompanied by a reversal of keratinocyte pathology and by selective depletion of intraepidermal T cells. J Exp Med 1995;182:2057-68.
21. Abrams JR, Kelley SL, Hayes E, Kikuchi T, Brown MJ, Kang S, et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte-associated antigen 4-immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000;192:681-94.
22. Gottlieb AB, Krueger JG, Wittkowski K, Dedrick R, Walicke PA, Garovoy M. Psoriasis as a model for T-cell-mediated disease: immunobiologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002;138:591-600.
23. Krueger JG, Gilleaudeau P, Kikuchi T, Lee E. Psoriasis-related subpopulations of memory CD4+ and CD8+ T cells are selectively reduced by alefacept [abstract]. J Invest Dermatol 2002;119:345.
24. Peckham PE, Weinstein GD, McCullough JL. The treatment of severe psoriasis. A national survey. Arch Dermatol 1987;123:1303-7.
25. Weinstein GD, Frost P. Methotrexate for psoriasis. A new therapeutic schedule. Arch Dermatol 1971;103:33-8.
26. Nyfors A. Benefits and adverse drug experiences during long-term methotrexate treatment of 248 psoriatics. Dan Med Bull 1978;25:208-11.
27. Rees RB, Bennett JH, Maibach HI, Arnold HL. Methotrexate for psoriasis. Arch Dermatol 1967;95:2-11.
28. Callaway JL, McAfee WC, Finlayson GR. Management of psoriasis using methotrexate orally in a single weekly dose. South Med J 1966;59:424-6.
29. Tristani-Firouzi P, Krueger GG. Efficacy and safety of treatment modalities for psoriasis. Cutis 1998;61:11-21.
30. Callis KP, Chadha A, Vaishnaw A, Krueger GG. Reduction of CD45RO+ effector T lymphocytes is not observed in the treatment of psoriasis with methotrexate [abstract]. J Invest Dermatol 2002;119:244.
31. Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: what defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
32. Relman AS. Assessment and accountability: the third revolution in medical care. N Engl J Med 1988;319:1220-2.
33. Epstein AM. The outcomes movement-will it get us where we want to go? N Engl J Med 1990;323:266-70.
34. McKenna KE, Stern RS. The outcomes movement and new measures of the severity of psoriasis. J Am Acad Dermatol 1996;34:534-8.
35. Touw CR, Hakkaart-Van Roijen L, Verboom P, Paul C, Rutten FF, Finlay AY. Quality of life and clinical outcome in psoriasis patients using intermittent cyclosporin. Br J Dermatol 2001;144:967-72.
36. Gregor JC MJ, Klar N, Wall R, Atkinson K, Lamba B, et al. An evaluation of the utility measurement in Crohn's disease. Inflamm Bowel Dis 1997;3:265-76.
37. Irvine EJ, Feagan B, Rochon J, Archambault A, Fedorak RN, Groll A, et al. Quality of life:a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology 1994;106:287-96.
38. Best WR, Becktel JM, Singleton JW. Rederived values of the eight coefficients of the Crohn's Disease Activity Index (CDAI). Gastroenterology 1979;77:843-6.
39. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
40. Buchbinder R, Bombardier C, Yeung M, Tugwell P. Which outcome measures should be used in rheumatoid arthritis clinical trials? Clinical and quality-of-life measures' responsiveness to treatment in a randomized controlled trial. Arthritis Rheum 1995;38:1568-80.
41. Tugwell P, Wells G, Strand V, Maetzel A, Bombardier C, Crawford B, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trialLeflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 2000;43:506-14.
42. Paulus HE, Bulpitt KJ, Ramos B, Park G, Wong WK. Relative contributions of the components of the American College of Rheumatology 20% criteria for improvement to responder status in patients with early seropositive rheumatoid arthritis. Arthritis Rheum 2000;43:2743-50.
43. Fortune DG, Main CJ, O'Sullivan TM, Griffiths CE. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997;137:755-60.
44. Wahl A, Moum T, Hanestad BR, Wiklund I. The relationship between demographic and clinical variables, and quality of life aspects in patients with psoriasis. Qual Life Res 1999;8:319-26.
45. Wall AR, Poyner TF, Menday AP. A comparison of treatment with dithranol and calcipotriol on the clinical severity and quality of life in patients with psoriasis. Br J Dermatol 1998;139:1005-11.
46. Wahl A, Hanestad BR, Wiklund I, Moum T. Coping and quality of life in patients with psoriasis. Qual Life Res 1999;8:427-33.
47. Kirby B, Richards HL, Woo P, Hindle E, Main CJ, Griffiths CE. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001;45:72-6.
48. Wahl A, Burckhardt C, Wiklund I, Hanestad BR. The Norwegian version of the Quality of Life Scale (QOLS-N). A validation and reliability study in patients suffering from psoriasis. Scand J Caring Sci 1998;12:215-22.
49. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum 1999;42:1870-8.
50. Gottlieb A, Matheson R, Lowe N, Krueger GG, Kang S, Goffe BS, et al. Etanercept (Enbrel) as monotherapy for the treatment of psoriasis. Arch Dermatol 2003;139:1627-32.
51. Felson DT, Anderson JJ, Lange ML, Wells G, LaValley MP. Should improvement in rheumatoid arthritis clinical trials be defined as fifty percent or seventy percent improvement in core set measures, rather than twenty percent? Arthritis Rheum 1998;41:1564-70.
52. Food and Drug Administration. Guidance for industry: Clinical development programs for drugs, devices and biological products for the treatment of rheumatoid arthritis [draft]: Rockville (MD): US Food and Drug Administration; 1999.